Literature DB >> 21326358

MeCP2: structure and function.

Nicholas L Adkins1, Philippe T Georgel.   

Abstract

Despite a vast body of literature linking chromatin structure to regulation of gene expression, the role of architectural proteins in higher order chromatin transitions required for transcription activation and repression has remained an under-studied field. To demonstrate the current knowledge of the role of such proteins, we have focused our attention on the methylated DNA binding and chromatin-associated protein MeCP2. Structural studies using chromatin assembled in vitro have revealed that MeCP2 can associate with nucleosomes in an N-terminus dependent manner and efficiently condense nucleosome arrays. The present review attempts to match MeCP2 structural domains, or lack thereof, and specific chromatin features needed for the proper recruitment of MeCP2 to its multiple functions as either activator or repressor. We specifically focused on MeCP2's role in Rett syndrome, a neurological disorder associated with specific MeCP2 mutations.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21326358     DOI: 10.1139/O10-112

Source DB:  PubMed          Journal:  Biochem Cell Biol        ISSN: 0829-8211            Impact factor:   3.626


  38 in total

1.  Proteomic cornerstones of hematopoietic stem cell differentiation: distinct signatures of multipotent progenitors and myeloid committed cells.

Authors:  Daniel Klimmeck; Jenny Hansson; Simon Raffel; Sergey Y Vakhrushev; Andreas Trumpp; Jeroen Krijgsveld
Journal:  Mol Cell Proteomics       Date:  2012-03-27       Impact factor: 5.911

2.  The stress oncoprotein LEDGF/p75 interacts with the methyl CpG binding protein MeCP2 and influences its transcriptional activity.

Authors:  Lai Sum Leoh; Bart van Heertum; Jan De Rijck; Maria Filippova; Leslimar Rios-Colon; Anamika Basu; Shannalee R Martinez; Sandy S Tungteakkhun; Valeri Filippov; Frauke Christ; Marino De Leon; Zeger Debyser; Carlos A Casiano
Journal:  Mol Cancer Res       Date:  2012-01-24       Impact factor: 5.852

Review 3.  The sex bias in systemic sclerosis: on the possible mechanisms underlying the female disease preponderance.

Authors:  Fabio D'Amico; Evangelia Skarmoutsou; Maria Clorinda Mazzarino
Journal:  Clin Rev Allergy Immunol       Date:  2014-12       Impact factor: 8.667

4.  De novo MECP2 duplications in two females with intellectual disability and unfavorable complete skewed X-inactivation.

Authors:  Nathalie Fieremans; Marijke Bauters; Stefanie Belet; Jelle Verbeeck; Anna C Jansen; Sara Seneca; Filip Roelens; Elfride De Baere; Peter Marynen; Guy Froyen
Journal:  Hum Genet       Date:  2014-07-19       Impact factor: 4.132

5.  Epigenetic suppression of neuroligin 1 underlies amyloid-induced memory deficiency.

Authors:  Bihua Bie; Jiang Wu; Hui Yang; Jijun J Xu; David L Brown; Mohamed Naguib
Journal:  Nat Neurosci       Date:  2014-01-19       Impact factor: 24.884

Review 6.  A review of Rett syndrome (RTT) with induced pluripotent stem cells.

Authors:  Vellingiri Balachandar; Venkatesan Dhivya; Mohan Gomathi; Subramaniam Mohanadevi; Balasubramanian Venkatesh; Bharathi Geetha
Journal:  Stem Cell Investig       Date:  2016-09-28

Review 7.  Investigation of Rett syndrome using pluripotent stem cells.

Authors:  Rana Dajani; Sung-Eun Koo; Gareth J Sullivan; In-Hyun Park
Journal:  J Cell Biochem       Date:  2013-11       Impact factor: 4.429

Review 8.  Breathing challenges in Rett syndrome: lessons learned from humans and animal models.

Authors:  Jan-Marino Ramirez; Christopher Scott Ward; Jeffrey Lorenz Neul
Journal:  Respir Physiol Neurobiol       Date:  2013-06-28       Impact factor: 1.931

Review 9.  Epigenetic layers and players underlying neurodevelopment.

Authors:  Janine M LaSalle; Weston T Powell; Dag H Yasui
Journal:  Trends Neurosci       Date:  2013-05-31       Impact factor: 13.837

Review 10.  New innovations: therapeutic opportunities for intellectual disabilities.

Authors:  Jonathan D Picker; Christopher A Walsh
Journal:  Ann Neurol       Date:  2013-09       Impact factor: 10.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.